THERAPEUTICS FOR ISCHEMIA-REPERFUSION INJURY

Protecting tissue when minutes determine outcome

Waventra Therapeutics is developing long half-life HGF mimetics designed to preserve tissue by protecting the microvasculature and cellular survival pathways during ischemia reperfusion injury. Ischemia reperfusion injury is a conserved failure mode that contributes to tissue loss across cardiology, neurology, trauma, cardiac surgery, organ transplantation and other acute care settings where restoring blood flow can paradoxically trigger further damage.

Lead indications: STEMI (heart attack)

Platform applications: Stroke, trauma, cardiac surgery, transplantation and more

THE PROBLEM: REPERFUSION INJURY continues AFTER FLOW IS RESTORED

1. OCCLUSION

Blocked artery deprives tissue of oxygen and nutrients

2. PCI RESTORES FLOW

PCI opens the artery and restores blood flow

3. THE WAVE OF DAMAGE

Reperfusion triggers inflammation, endothelial injury and cell death can continue for hours

4. WAV-301 INTERRUPTS THE DAMAGE

WAV-301 protects the microvasculature and stabilizes cells during reperfusion, preserving tissue and function

TARGETS MICROVASCULAR INJURY

Protects the small vessels where reperfusion injury begins

SINGLE DOSE IV ADMINISTRATION

Designed for rapid practical use in acute care settings

LONG HALF-LIFE HGF MIMETIC

Engineered for sustained protection when it matters most

ACUTE IMPACT

Acts at the critical moment to limit damage and preserve tissue

A PLATFORM BUILT FOR A UNIVERSAL PROBLEM. A THERAPY DESIGNED TO CHANGE OUTCOMES.